Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
Volume: 29, Issue: 4, Pages: 258 - 264
Published: Apr 27, 2020
Abstract
Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype. Programmed death ligand 1 (PD-L1) on immune cells (IC) using the VENTANA SP142 assay is linked to improved clinical outcome in atezolizumab plus nab—paclitaxel-treated patients with mTNBC in the IMpassion130 study. The goal of the current study was to evaluate prevalence of VENTANA SP142 PD-L1 assay by anatomic location in 670 histologically confirmed...
Paper Details
Title
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
Published Date
Apr 27, 2020
Volume
29
Issue
4
Pages
258 - 264
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History